GBA1 and Gaucher disease type I: Several plant-produced therapeutics (Kizhner et al., 2015; Ma et al., 2015; Mor, 2015; Prevail Ii Writing Group et al., 2016) and vaccines (Yuki et al., 2013; Hendin et al., 2017; Donini and Marusic, 2019) are currently in pipeline for clinical trials and approval, Notably plant-produced Glucocerebrosidase enzyme (ElelysoTM) for the treatment of type I Gaucher’s disease has been approved by US Food and Drug Administration (Fox, 2012) and tobacco-derived seasonal flu VLP vaccine from Medicago Inc., is currently in final stages of clinical trial (Ward et al., 2021).